Description: A Phase 1, First-In-Human Study of IK-930, An oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Target Patient Population: All solid tumors
Study Design: Study Drug is given orally.
Phone: (800) 411-7999
